Get the Stockscreener App
0.134
80.66%
-0.559
After Hours:
.14
0.006
+4.48%
Affimed N V stock is traded at $0.134, with a volume of 9.72M.
It is down -80.66% in the last 24 hours and down -78.46% over the past month.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
See More
Previous Close:
$0.693
Open:
$0.1615
24h Volume:
9.72M
Relative Volume:
39.28
Market Cap:
$13.53M
Revenue:
$19.91M
Net Income/Loss:
$-127.11M
P/E Ratio:
-0.0159
EPS:
-8.428
Net Cash Flow:
$-132.44M
1W Performance:
-83.04%
1M Performance:
-78.46%
6M Performance:
-96.43%
1Y Performance:
-97.45%
1-Day Range:
$0.13
$0.1767
1-Week Range:
$0.13
$0.80
52-Week Range:
$0.13
$8.95
Affimed N V Stock (AFMD) Company Profile
Compare AFMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AFMD
Affimed N V
|
0.134 | 13.53M | 19.91M | -127.11M | -132.44M | -8.428 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-22 | Initiated | H.C. Wainwright | Buy |
| Oct-10-22 | Downgrade | Stifel | Buy → Hold |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-23-22 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-21 | Initiated | Truist | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Aug-28-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Aug-12-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| May-19-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Dec-10-15 | Initiated | Laidlaw | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Sep-09-15 | Initiated | Jefferies | Hold |
| Aug-06-15 | Reiterated | Oppenheimer | Outperform |
| Jun-22-15 | Reiterated | Jefferies | Buy |
View All
Affimed N V Stock (AFMD) Latest News
Health Care Stocks Face Broad Downturn As Sector Challenges Mount - Finimize
Affimed (AFMD) Faces Downgrade Amid Insolvency Proceedings | AFM - GuruFocus
Wells Fargo Downgrades Affimed (AFMD) with New Price Target | AF - GuruFocus
Affimed downgraded to Equal Weight at Wells after insolvency filing - TipRanks
Wells Fargo Downgrades Affimed to Equalweight From Overweight; Shares Plunge - marketscreener.com
Crude Oil Gains 3%; US Inflation Eases In April - Benzinga
Affimed (AFMD) Files for Insolvency Amid Financial Challenges - GuruFocus
Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales - Benzinga
Affimed (AFMD) Seeks Insolvency Proceedings Amid Financial Strug - GuruFocus
Affimed (AFMD) Resumes Trading, Offering Market Opportunities | - GuruFocus
Affimed shares crash after filing for the opening of insolvency proceedings - MSN
Affimed Announces Filing for the Opening of Insolvency Proceedin - GuruFocus
Affimed Shares Down, Halted in Premarket on Bankruptcy Application - MarketWatch
Affimed Files for Insolvency Amid Financial Challenges - TipRanks
This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Affimed Announces Filing for the Opening of Insolvency Proceedings - GlobeNewswire
This Rapid7 Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday - Benzinga
AFMD: Leerink Partners Downgrades Affimed with New Price Target - GuruFocus
Affimed (AFMD) Downgraded as Funding Prospects Dim | AFMD Stock News - GuruFocus
Leerink Downgrades Affimed to Market Perform From Outperform - marketscreener.com
Leerink cuts Affimed stock target to $0.39, downgrades rating By Investing.com - Investing.com India
Affimed (NASDAQ:AFMD) Now Covered by StockNews.com - Defense World
Affimed N.V.: Q2 Earnings Snapshot - Barchart.com
Affimed Delays Filing of 2024 Yearly Report - TipRanks
Affimed Shows Higher Exposure of AFM24 is Associated with Signif - GuruFocus
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting | AFMD Stock News - GuruFocus
Affimed Shows Higher Exposure of AFM24 is Associated with - GlobeNewswire
Affimed N.V. Reports Positive Findings on AFM24's Exposure-Outcome Analysis in Refractory Non-Small Cell Lung Cancer Patients - Nasdaq
Breakthrough: AFM24 Cancer Drug Achieves 33% Response Rate in Lung Cancer with New Dosing Strategy - Stock Titan
Affimed (NASDAQ:AFMD) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Affimed (NASDAQ:AFMD) Coverage Initiated at StockNews.com - Defense World
Affimed Announces Acceptance of Three Abstracts for Presentation - GuruFocus
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting | AFMD Stock News - GuruFocus
Affimed N.V. Announces Accepted Abstracts for Oral and Poster Presentations at ASCO 2025 Annual Meeting - Nasdaq
Affimed Announces Acceptance of Three Abstracts for - GlobeNewswire
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting - TradingView
Affimed Secures Coveted Oral Presentation Slot at ASCO 2025: Phase 2 Lymphoma and Lung Cancer Data - Stock Titan
Affimed faces Nasdaq delisting over share price rule By Investing.com - Investing.com Canada
Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode - NewsBreak: Local News & Alerts
Affimed Faces Nasdaq Delisting Risk Due to Share Price - TipRanks
Affimed faces Nasdaq delisting over share price rule - Investing.com Australia
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding - GuruFocus
Affimed (AFMD) Faces Nasdaq Delisting Risk Due to Low Share Price | AFMD Stock News - GuruFocus
Affimed (AFMD) Faces Nasdaq Delisting Risk Over Share Price - GuruFocus
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | AFMD Stock News - GuruFocus
Affimed N.V. Receives Nasdaq Notification Regarding Minimum Bid Price Compliance - Nasdaq
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewswire
Affimed Gets 180-Day Nasdaq Grace Period After Stock Falls Below $1, Extension Possible - Stock Titan
Affimed N.V. Receives EUR 2.4 Million Research Grant from German Government to Fund Trispecific Abs - marketscreener.com
Affimed (NASDAQ:AFMD) Now Covered by Analysts at StockNews.com - Defense World
Affimed N V Stock (AFMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):